A Study of QLS1128 and in Combination With Ritonavir in Healthy Participants

NCT05458076 · clinicaltrials.gov ↗

PHASE1

Phase

UNKNOWN

Status

86

Enrollment

INDUSTRY

Sponsor class

Conditions

COVID-19

Interventions

DRUG: QLS1128 A-Dose 1~5 and Ritonavir
DRUG: QLS1128 C-Dose 1~3 and Ritonavir
DRUG: QLS1128 D-Dose 1 and Ritonavir

Sponsor

Qilu Pharmaceutical Co., Ltd.